Clinical Impact of Adherence to NCCN Guidelines for Biomarker Testing and First-Line Treatment in Advanced Non-Small Cell Lung Cancer (aNSCLC) Using Real-World Electronic Health Record Data

被引:0
作者
Ani John
Baiyu Yang
Roma Shah
机构
[1] Roche Diagnostics,
来源
Advances in Therapy | 2021年 / 38卷
关键词
Adherence; Biomarker; First-line treatment; Guidelines; Non-small cell lung cancer; Precision medicine;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:1552 / 1566
页数:14
相关论文
共 48 条
[1]  
Millner LM(2016)The future of precision medicine in oncology Clin Lab Med 36 557-573
[2]  
Strotman LN(2018)A review of guidelines for lung cancer J Thorac Dis 10 S1556-S1563
[3]  
Bironzo P(2020)Therapy for stage IV non–small-cell lung cancer without driver alterations: ASCO and OH (CCO) joint guideline update J Clin Oncol 38 1608-1632
[4]  
Di Maio M(2013)Rates of guideline adherence among US community oncologists treating NSCLC Am J Manag Care 19 185-192
[5]  
Hanna NH(2006)Results of the National Initiative for Cancer Care Quality: how can we improve the quality of cancer care in the United States? J Clin Oncol 24 626-634
[6]  
Schneider BJ(2012)Factors associated with adherence to chemotherapy guidelines in patients with non-small cell lung cancer Lung Cancer 75 255-260
[7]  
Temin S(2017)EP-1221: adherence to lung cancer guidelines and its impact on survival Radiother Oncol 123 S659-242
[8]  
Wang Z(2020)Real-world adherence to guideline-recommended treatment for small cell lung cancer Am J Clin Oncol 43 236-542
[9]  
Askamit I(2020)Comparison of population characteristics in real-world clinical oncology databases in the US: Flatiron Health, SEER, and NPCR medRxiv 39 531-54
[10]  
Tuscher L(2019)Biomarker testing for patients with advanced non-small cell lung cancer: real-world issues and tough choices Am Soc Clin Oncol Educ Book 4 49-e119